Dynamic Combination Therapy on Chinese Herbal Granules to Improve the Symptoms in Convalescent Phase of Ischemic Stroke

Inclusion criteria

• Age: 18 - 75 years.
• Clinical diagnosis of ischemic stroke causing a measurable neurological deficit defined as impairment of language, motor function, cognition and/or gaze, vision or neglect, confirmed by CT or MRI scan.
• Clinical diagnosis of "Qixu-Xueyu Zheng" (Qi deficiency and Blood Stasis Syndrome) as the scores of Chinese medicine symptoms scales in ischemic stroke on both "Qixue" and "Xueyu" ≥ 7.
• 15 days to 60 days after onset of symptoms.
• Clinical diagnosis of cerebral anterior circulation obstruction.
• 4≤NIHSS<20.
• Patient is willing to participate voluntarily and to sign a written patient informed consent.

Exclusion criteria

• Transient ischemic attack
• Evidence of intracranial hemorrhage (ICH) in 6 months
• Evidence of other cerebral diseases (eg.vascular malformation, tumor, abscess or multiple sclerosis etc.)on the CT or MRI scan.
• Woman with pregnancy, lactation or positive result of pregnancy test, or women who want to be pregnant in recent 6 months.
• Woman who is under menstrual period.
• Known history of allergy or suspected allergic to these chinese herbs.
• Complicated with atrial fibrillation.
• Fasting blood glucose ≥8 mmol / l under the treatment of diabetes or complicated with severe cardio-cerebrovascular diseases (eg. hyperlipemia, coronary heart disease with angina attack ≥ 4 times a day).
• Liver function impairment with the value of ALT or AST over 1.5-fold of normal value.
• Renal dysfunction with the value of serum creatinine over normal value.
• Prior disable patients or complicated with osteoarthropathy that influence the motor function of the limbs.
• With mental disorder that can not cooperate with doctor
• Suspected addicted into alcohol or drug abuse.
• With severe complications that would make the condition more complicated assessed by the investigator.
• Patient who is participating in other trials or has been participated in other trials in recent 3 months.